Immunogenicity risk assessment is a science-based evaluation process that identifies and characterizes the potential of medical devices, biomaterials, and biotherapeutic products to induce unintended immune responses in patients. Aligned with ISO 10993-1, ISO 10993-20, and ISO 14971, a systematic immunogenicity evaluation supports biological safety documentation, regulatory submissions, and informed material selection throughout the product lifecycle.
Technical Overview
Immunogenicity risk assessment is the systematic, risk-based evaluation of the likelihood that a medical device, biomaterial, or biotherapeutic product will trigger an undesirable immune response in a patient. Such responses may include hypersensitivity reactions, inflammation, complement activation, anti-drug antibody (ADA) formation, or neutralization of therapeutic activity. The assessment integrates material characterization, toxicological data, immunological testing, and clinical context to determine whether the immunogenic potential of a product is acceptable within its intended use.
The evaluation framework is structured around international standards, principally ISO 10993-1 (biological evaluation of medical devices within a risk management process), ISO 10993-17 (toxicological risk assessment), and ISO 10993-20 (principles and methods for immunotoxicology testing of medical devices). Risk management activities are conducted in accordance with ISO 14971. For protein- and peptide-based therapeutics, additional guidance from ICH S6 and ICH S8 is often applied. A key principle of the current standards is the preference for chemical characterization and in vitro methods before in vivo animal testing, consistent with the 3Rs philosophy of reducing, refining, and replacing animal use.
Immunogenicity risk is driven by multiple product- and patient-related factors. Product-related factors include material chemistry, extractables and leachables, surface topology, protein adsorption and conformational changes, aggregation, degradation products, residual manufacturing impurities, and sterilization residues. Patient-related factors include route and duration of exposure, frequency of administration, immune status, genetic background, and prior sensitization. A comprehensive risk assessment weighs each of these variables to define an appropriate testing strategy and, where necessary, mitigation measures.
Testing Samples
Medical Devices and Device Extracts
Direct or indirect contact devices such as permanent implants, orthopedic hardware, cardiovascular devices, catheters, infusion sets, wound dressings, surgical meshes, dental materials, and contact lenses. Testing is typically performed on polar and non-polar extracts prepared under exaggerated and intended-use extraction conditions, following the sample preparation requirements of ISO 10993-12.
Biomaterials and Raw Materials
Polymers, metals and alloys, ceramics, hydrogels, coatings, adhesives, and elastomers evaluated during early-stage material screening and selection. Candidate materials are compared for their potential to elicit inflammatory, sensitizing, or complement-activating effects before they are incorporated into a final device design.
Biopharmaceuticals and Biologics
Monoclonal antibodies, recombinant proteins, fusion proteins, enzymes, peptides, antibody-drug conjugates, and nucleic acid-based products. For these molecules, the assessment focuses on the risk of anti-drug antibody formation, including binding antibodies and neutralizing antibodies that may alter pharmacokinetics, safety, or efficacy.
Combination and Drug-Eluting Products
Drug-eluting stents, prefilled syringes, autoinjectors, implantable delivery systems, and other drug-device or biologic-device combination products. These products require integrated evaluation because both the active substance and the device construct can contribute independently or synergistically to immune activation.
Process-Related and Impurity Samples
Extractables and leachables profiles, residual host-cell proteins, residual solvents, processing aids, degradation products, leached nanoparticles, and sterilization residues. These samples are used to identify immunologically active entities that may act as adjuvants or haptens and amplify an immune response.
Testing Items
- Hypersensitivity potential, including Type I through Type IV reactions and material-mediated sensitization
- Complement activation, measured via cleavage products and terminal pathway complexes such as C3a, C5a, and SC5b-9
- Cytokine and chemokine release profiles, including IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, TNF-α, IFN-γ, and GM-CSF
- Lymphocyte proliferation and T-cell reactivity following exposure to test materials or extracts
- Anti-drug antibody evaluation, covering screening assays, confirmatory assays, titration, isotyping, and immunoglobulin subclass profiling
- Neutralizing antibody assays that detect functional inhibition of product activity
- Dendritic cell maturation and activation markers, including CD80, CD86, CD83, CD40, and HLA-DR expression
- Innate immune cell activation, including monocyte and macrophage activation, phagocytosis, and oxidative burst responses
- Pyrogenicity and inflammation screening, covering bacterial endotoxin and non-endotoxin pyrogens
- Systemic and local immunotoxicity endpoints, such as hematology, lymphoid organ weights, and histopathology of spleen, thymus, and lymph nodes
- In silico and ex vivo T-cell epitope mapping for sequence-based immunogenicity prediction of biologics
Testing Methods
The testing strategy follows a tiered, weight-of-evidence approach. The first tier involves physicochemical characterization and hazard identification, in which material composition, extractables profiles, and known immunological hazards are documented. The second tier applies screening assays to detect immune activation, and the third tier performs confirmatory and functional studies where a potential risk has been identified.
In vitro methods form the core of modern immunogenicity testing. Enzyme-linked immunosorbent assays (ELISA) are used to quantify antibodies, cytokines, and complement fragments. Multiplex bead-based assays enable simultaneous measurement of dozens of cytokines from small sample volumes. ELISpot and FluoroSpot assays quantify antigen-specific cytokine-secreting cells at the single-cell level. Flow cytometry supports immunophenotyping of lymphocyte subsets, dendritic cell maturation markers, and activation markers such as CD69 and CD25. Lymphocyte proliferation is assessed using carboxyfluorescein succinimidyl ester (CFSE) dilution, BrdU incorporation, or thymidine uptake. Complement activation assays are performed in human pooled serum under standardized incubation conditions.
Where in vivo data are required, sensitization studies such as the guinea pig maximization test, the Buehler patch test, or the murine local lymph node assay (conducted in line with OECD Test Guideline 429) may be applied. For biotherapeutics, surface plasmon resonance (SPR) and electrochemiluminescence platforms are used for high-sensitivity ADA detection, while cell-based neutralization assays measure functional antibody impact. In silico tools for peptide-MHC binding prediction and T-cell epitope identification allow early risk triage before wet-lab studies are initiated. All studies are performed by accredited third-party laboratories under GLP or GMP-aligned quality systems, ensuring data integrity and regulatory acceptance.
Applications
- Biological safety evaluation of medical devices and preparation of ISO 10993-1 biological evaluation plans and reports for regulatory submissions
- Technical documentation support for device registration, design change justification, and equivalence assessments
- Risk management file development and benefit-risk analysis in accordance with ISO 14971
- Immunogenicity strategy development for novel biologics, biosimilars, and follow-on biopharmaceuticals
- Material screening, ranking, and selection during research and development to avoid costly late-stage failures
- Evaluation of sterilization, packaging, and process changes that may alter the immunological profile of a product
- Post-market surveillance, complaint investigation, and adverse event root-cause analysis
- Vendor qualification and incoming material control for manufacturers
- Support for combination product dossiers in which drug, biologic, and device components interact immunologically
FAQ
What is immunogenicity risk assessment?
It is a structured evaluation of the probability and clinical consequence of an unwanted immune response caused by a device, material, or biologic. The assessment combines chemical characterization, immunological testing, and clinical context to determine whether the risk is acceptable and whether mitigation measures are needed.
Which standards govern the assessment?
The primary framework is the ISO 10993 series, particularly ISO 10993-1 for the risk-based evaluation process, ISO 10993-17 for toxicological risk assessment, and ISO 10993-20 for immunotoxicology testing. Risk management activities follow ISO 14971, and biologics-related evaluation may reference ICH S6 and ICH S8.
When is a formal assessment required?
A formal assessment is expected whenever a new device contacts the body or its fluids, whenever materials or manufacturing processes change, whenever a new biologic enters development, and whenever regulatory submissions require documented biological safety or immunogenicity justification.
What is the difference between immunogenicity and immunotoxicity?
Immunogenicity refers to the ability of a substance to provoke an immune response, such as antibody formation or T-cell sensitization. Immunotoxicity refers to adverse effects on the structure or function of the immune system, such as immunosuppression or immune dysregulation. Both aspects are addressed within a comprehensive evaluation under ISO 10993-20.
Can the evaluation be performed entirely in vitro?
In many cases, yes. Current standards encourage a chemical characterization and in vitro first approach. Human-cell-based assays covering cytokine release, complement activation, and dendritic cell maturation can often close risk questions without animal testing. In vivo studies are reserved for cases where in vitro data are inconclusive or where regulatory expectations require them.
What factors most strongly influence immunogenicity risk?
Key drivers include the chemical nature of extractables and leachables, protein aggregation, surface properties, degradation behavior, exposure route and duration, and the immune status of the patient population. A well-documented characterization dossier substantially strengthens the overall risk conclusion.
How should a testing program be initiated?
The recommended starting point is a documented biological evaluation plan that defines intended use, contact classification, materials of construction, and existing data gaps. Based on this plan, a tailored testing matrix is designed, ensuring that only scientifically justified endpoints are evaluated, which reduces both cost and timelines.